The Global Genetic Testing Market was valued at USD 17.48 billion in 2023 and is projected to reach USD 46.29 billion by 2032, with a CAGR of 11.34%. Factors driving growth include the increase in genetic disorders, cancer cases, technological advancements, and rising demand for personalized medicine. Major players in the market include Illumina, 23andMe, Myriad Genetics, and more.

The market growth is fueled by the need for early diagnosis and targeted treatment of genetic conditions. Technological advancements have significantly reduced sequencing costs, making genetic testing more accessible. In 2023, over 10 million cancer deaths were linked to genetic mutations, highlighting the importance of genetic testing in healthcare.

North America held a 43.25% market share in 2023, while Asia Pacific is expected to grow at a CAGR of 13.51% from 2024-2032. The region’s growth is attributed to increased healthcare spending, infrastructure development, and rising awareness of genetic abnormalities. Illumina and 23andMe are driving genomic testing adoption in oncology and releasing new genetic risk reports for users.

The Genetic Testing Market offers lucrative opportunities for market players with the increasing demand for personalized healthcare. By segmenting the market based on technology, application, product, channel, and end-use, companies can target specific areas for growth. Regional utilization trends and healthcare spending insights provide valuable information for strategic planning and investment decisions.

Read more at GlobeNewswire: Genetic Testing Market Size Projected to Reach USD 46.29